Please login to the form below

Not currently logged in
Email:
Password:

Servier

This page shows the latest Servier news and features for those working in and with pharma, biotech and healthcare.

CAR-Ts take centre stage as ASH18 comes to a close

CAR-Ts take centre stage as ASH18 comes to a close

Among the highlights, Allogene and partner Servier presented phase 1 data for its ‘off-the-shelf’ CAR-T therapy UCART19 in acute lymphoblastic leukaemia (ALL), making the case for an easier

Latest news

More from news
Approximately 16 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    The Xoma licensing deal is interesting because it required Novartis to settle the $14m debt owed to Xoma’s previous licensee Servier.

  • Deal Watch March 2017 Deal Watch March 2017

    name. (Abexinostat was formerly in development by Pharmacyclics (now owned by AbbVie) and Servier.) Both ACAT-1 (for which Xynomic paid $1.2m upfront with another $59m in potential milestones) and

  • Deal Watch January 2017 Deal Watch January 2017

    What goes around, comes around The appetite for immuno-oncology (IO) has survived well into 2017 with Servier closing the biggest IO headline deal in January with Pieris for $1.7bn ... 3, 050. Pieris Pharmaceuti-cals. Servier. Exclusive licence outside

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Licence. 1, 115. Sorrento Therapeutics/ Servier. STI-A1110 - anti-PD1

  • Searching for health Searching for health

    The 27 hectare site, with two production plants making pharmaceuticals and cosmetics, is a crucial springboard for new therapies and the industry-wide commitment to rebuild after Servier's appetite suppressant

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics